Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.

Sickle hemoglobin (Hb S; beta Glu6Val) is due to an A > T transversion in codon 6 of the beta-globin gene. Other variant hemoglobins mimic Hb A, S, or C on newborn screening and clinical laboratory diagnostic tools, thus making their correct identification potentially difficult. Sickling disorders can result in individuals who are compound heterozygous for beta-globin mutations (e.g., Hb SC, HbSO(Arab)). The authors report a second case of HbS/ Quebec-CHORI, a severe compound heterozygous sickling disorder and their experience managing this patient with hydroxyurea.